NCT06725303

Brief Summary

The aim is to assess the efficacy and safety of Excimer Light versus blue light in the treatment of inflammatory acne.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2025

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 8, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 10, 2024

Completed
6 months until next milestone

Study Start

First participant enrolled

June 1, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2025

Completed
Last Updated

May 14, 2025

Status Verified

May 1, 2025

Enrollment Period

1 month

First QC Date

December 8, 2024

Last Update Submit

May 10, 2025

Conditions

Acne Vulgaris

Outcome Measures

Primary Outcomes (1)

  • Number of comedones, papules and pustules

    number of lesions

    2 months

Study Arms (2)

Excimer light

EXPERIMENTAL

Light energy

Device: Excimer

Blue light

ACTIVE COMPARATOR

Light energy

Device: Excimer

Interventions

ExcimerDEVICE

Light energy

Blue lightExcimer light

Eligibility Criteria

Age18 Years - 25 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients with mild to moderate inflammatory acne lesions

You may not qualify if:

  • Pregnancy during the first trimester
  • Female patients with a medical history of PCO
  • Topical and systemic treatment within the last month and systemic retinoids for 6 months
  • Patients on systemic steroid treatment or hormonal therapy
  • Severe systemic illness or malignancy
  • Photosensitivity
  • Scarring acne vulgaris

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Lasers, Excimer

Condition Hierarchy (Ancestors)

Acneiform EruptionsSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

LasersOptical DevicesEquipment and SuppliesRadiation Equipment and Supplies

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
University doctor

Study Record Dates

First Submitted

December 8, 2024

First Posted

December 10, 2024

Study Start

June 1, 2025

Primary Completion

July 1, 2025

Study Completion

October 1, 2025

Last Updated

May 14, 2025

Record last verified: 2025-05